Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.4%

3 terminated out of 87 trials

Success Rate

93.2%

+6.6% vs benchmark

Late-Stage Pipeline

8%

7 trials in Phase 3/4

Results Transparency

5%

2 of 41 completed with results

Key Signals

2 with results93% success

Data Visualizations

Phase Distribution

72Total
Not Applicable (59)
Early P 1 (3)
P 1 (1)
P 2 (2)
P 3 (4)
P 4 (3)

Trial Status

Completed41
Recruiting17
Unknown11
Not Yet Recruiting6
Active Not Recruiting4
Enrolling By Invitation3

Trial Success Rate

93.2%

Benchmark: 86.6%

Based on 41 completed trials

Clinical Trials (87)

Showing 20 of 20 trials
NCT07655375Not ApplicableRecruitingPrimary

Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut

NCT06889779Not ApplicableCompletedPrimary

Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms

NCT07699926Not ApplicableCompletedPrimary

Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome

NCT07591584Not ApplicableRecruitingPrimary

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

NCT07543354Not ApplicableNot Yet RecruitingPrimary

Personalized Therapy of Long-term Low FODMAP in IBS Treatment: Role of Mobile Application and "Microbiota-gut-brain" Axis

NCT07584473Not ApplicableRecruiting

NCWS or IBS/FD in Relatives of CD Patients

NCT07309601Not ApplicableRecruitingPrimary

Sucrase-Isomaltase (SI) Genes and Meal Load

NCT07540312Not ApplicableRecruitingPrimary

A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome

NCT07089420Completed

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07539077Completed

Prevalence of Disorders of Gut-Brain-Interaction in Pediatric Patients With In-remission Inflammatory Bowel Disease

NCT06727422Phase 2RecruitingPrimary

Efficacy of Rifaximin With NAC in IBS-D

NCT07534930Not ApplicableActive Not RecruitingPrimary

Personalised Multidisciplinary Treatment in Moderate to Severe IBS

NCT07517029RecruitingPrimary

Gut Microbiome in Patients With Post-infectious Irritable Bowel Syndrome

NCT05815602Phase 3RecruitingPrimary

Ebastine Versus Mebeverine in IBS Patients

NCT07471490Enrolling By Invitation

Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.

NCT05995899Phase 4Completed

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

NCT06760533Early Phase 1Not Yet RecruitingPrimary

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

NCT07424898Enrolling By Invitation

Lactose Intolerance and Intestinal Permability

NCT06993272Not ApplicableActive Not RecruitingPrimary

Relaxation Music for Chronic Pain

NCT06297785Not ApplicableCompletedPrimary

Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)

Scroll to load more

Research Network

Activity Timeline